Sepsis Interdisciplinary 研究 Center (SIRC) at SUNY 推荐最近最火的赌博软件 Medical University
The term sepsis describes the overwhelming host response to infection. Sepsis is a major and very challenging medical problem, annually impacting 1.7 M Americans and causing 270,000 deaths. Sepsis is the leading cause of death in hospital. The mortality rate of sepsis remains high although huge efforts have been invested in sepsis research and treatments. Due to the complexity of sepsis, none of the experimental therapeutics developed over the last decades have proven to be effective. 在脓毒症, the combination of severe infection and host response to infection causes systemic inflammation and tissue damage. The release of damage-associated and pathogen-associated molecular pattern molecules (DAMPs and PAMPs) activate the innate immune system by interacting with pattern recognition receptors. Therefore, tissue damage during some critical illness, e.g. 创伤, 燃烧, acute lung injury (ALI), 肝硬化, and pancreatitis can result in sepsis via a common pathophysiological pathway, i.e. systemic inflammatory response syndrome (SIRS) (方案1), which further leads to septic shock, multiple organ failure and potentially death.
方案1. Illustration of sepsis induced by both infections and 创伤tic tissue injury through a common pathophysiological process, e.g. systemic inflammatory response syndrome (SIRS). A novel nanotrap hemoperfusion approach has been developed in Dr. Juntao罗’s Lab at SUNY 推荐最近最火的赌博软件 Medical University to 有选择性地 scavenge a broad range of septic triggers, mediators and signalling molecules to attenuate hyperinflammation in sepsis and critical illness patients.
Dr. Juntao罗 at SUNY 推荐最近最火的赌博软件 Medical University has developed an innovative nanotrap technology to attenuate the host’s inflammatory response to infection by scavenging a broad range of PAMPs and DAMPs. This novel nanotrap technology can be designed to target specific pro- or anti-inflammatory signaling molecules, 有选择性地, 因此, precisely controlling immune responses. Nanotrap technology can be applied systemically (nanoparticles), or locally at the site of infection (nanogel and hydrogel), or extracorporeally as hemoperfusion cartridges at different stages of infection/sepsis to modulate the host’s immune response. This novel technology promises to make a breakthrough and fulfill the unmet clinical need for sepsis treatments. Through collaboration, these nanotrap approaches are being evaluated in clinically applicable large animal models to demonstrate the evidence-based efficacy for sepsis treatment at both molecular and systemic levels for clinical translation.
脓毒症的研究 at 推荐最近最火的赌博软件
Sepsis research at 推荐最近最火的赌博软件 has a long history, focusing on preclinical and translational research aimed at developing and evaluating therapeutic approaches for sepsis treatment in highly clinically-relevant porcine sepsis models. In response to the National initiative in solving sepsis through driving innovation and accelerating transformative technologies, Dr. 罗伯特·库尼, MD, Professor and Chair of Surgery, and Dr. Juntao罗, 博士学位, Associate professor of Pharmacology, have co-founded the Sepsis Interdisciplinary 研究 Center (SIRC) and serve as co-directors to modulate research collaborations and grant applications in translational sepsis research.
SIRC is a highly collaborative and integrative research group with synergistic and multidisciplinary expertise from therapeutic development, 分子生物学, 免疫学, pathophysiology and clinical care. Eight laboratories in the Department of Pharmacology and the Department of Surgery are actively conducting research in sepsis, 创伤, 伤口愈合, pulmonary and hematological diseases, funded by multiple active federal grants, including four NIH R01 grants, 和一下R21, NSF, 和国防部奖项.